Feverfew Tanacetum parthenium (L.) Schultz Bip.
Also called: Chrysanthemum parthenium, Matricaria parthenium
A perennial plant from western Asia and the Balkans, now grown worldwide, used traditionally for fever and many other complaints and now promoted for migraine. Not the same plant as American feverfew (Parthenium integrifolium).
- Category
- Botanical
- Part used
- Herb (Tanaceti parthenii herba in the EU monograph); leaves
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 2 Moderately studied in people. A 2015 Cochrane review found 6 randomized, placebo-controlled, double-blind trials (561 patients) of feverfew monopreparations for migraine; pooling was not possible because outcome measures, participants, interventions and designs differed. [3]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep3 topics
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Migraine frequency (Cochrane review) | C | Six trials (561 participants), mixed and inconclusive. In the largest (218 people), attacks fell from 4.8 to 2.9 per month versus 4.8 to 3.5 with placebo; two rigorous trials found no difference. Low-quality evidence. [3] |
| Migraine (later review) | C | A 2020 review of 7 studies (634 participants) found inconsistent results; studies were small and used different sources and doses. [1] |
| Migraine pain severity and attack duration | C | The Cochrane review found no difference from placebo in pain severity or attack duration; the evidence was rated low quality. [3] |
| Other health conditions | C | NCCIH reports little or no evidence for any condition other than migraine. [1] |
Main constituents: Sesquiterpene lactones, particularly parthenolide, are considered the active constituents [2]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNCCIH: do not take feverfew while pregnant because it may affect uterine contractions; little is known about safety while breastfeeding.
1 statement in the profile.
Details and sources - Interactions with medicines3 listed
Anticoagulants and antiplatelet drugs; Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4; Migraine medicines
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU herbal monograph on Tanacetum parthenium (L.) Schultz Bip., herba (EMA/HMPC/48715/2017, Revision 1, 8 July 2020), traditional use for migraine …
Details and sources
- No serious side effects have been reported; possible effects include nausea, digestive problems and bloating. Chewing fresh leaves may cause mouth sores and irritation. [1]
- In trials, adverse events were mild and transient, most commonly gastrointestinal complaints and mouth ulcers. [3]
- Stopping after long-term use may be followed by muscle stiffness, anxiety and moderate pain ('post-feverfew syndrome'). [2]
- May slow blood clotting; stop at least 2 weeks before scheduled surgery. [1]
- People sensitive to ragweed and related plants may have allergic reactions; topical use may cause dermatitis. [1]
- Pregnancy: do not use, as it may affect uterine contractions. Safety while breastfeeding is largely unknown. [1]
Interactions
| With | What happens |
|---|---|
| Migraine medicines | Feverfew may interact with some medicines, including migraine medications. [1] |
| Anticoagulants and antiplatelet drugs | Its active constituent inhibits platelet activity and may have additive effects; clinical relevance is not known. [2] |
| Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4 | Feverfew inhibits these enzymes and can affect concentrations of drugs they metabolize; clinical relevance is not known. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Trials used different feverfew sources and doses; Cochrane reviewers called for larger rigorous trials using stable feverfew extracts. [3]
Regulatory status
- US: sold as a dietary supplement ingredient; supplements are not FDA-approved before sale. [1]
- EU: European Union herbal monograph based on traditional use for migraine prophylaxis after serious conditions have been excluded by a doctor; clinical trials were judged insufficient for well-established use. [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Sesquiterpene lactones, particularly parthenolide (MSK: the active constituents responsible for feverfew's effects) Sesquiterpene lactones and other lactones [P6]
- Parthenolide appears mainly responsible for the antisecretory effect of feverfew extracts on blood platelets (in vitro bioassay) Sesquiterpene lactones and other lactones [P7]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming feverfew (Tanacetum parthenium) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Anticoagulants and antiplatelet drugs: Feverfew's active constituent inhibits platelet activity and may have additive effects; clinical relevance is not known. [P6]
- Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4: Feverfew inhibits these enzymes and can affect concentrations of drugs they metabolize; clinical relevance is not known. [P6]
- Migraine medicines: NCCIH: feverfew may interact with some medicines, including those used for migraine. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Purported feverfew products varied widely in parthenolide content and in some none was detected; parthenolide level in powdered leaf fell during storage (Heptinstall et al., 1992). [P7]
- In US feverfew products, parthenolide per dosage form varied 150-fold (0.02 to 3.0 mg) and percent parthenolide 5.3-fold (0.14% to 0.74%) (Nelson et al., 2002). [P8]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
- Parthenolide assay (HPLC) — Authors of a product survey recommended parthenolide measurement for standardization and quality control because commercial products varied widely and some contained none. [P7]
Supply and conservation
- Feverfew is native to parts of western Asia and the Balkans, but it now grows throughout the world. [P5]
Absorption in people
- In a phase I trial in patients with cancer, feverfew providing up to 4 mg parthenolide daily gave no detectable parthenolide in plasma (limit of detection 0.5 ng/mL). [P9]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU herbal monograph on Tanacetum parthenium (L.) Schultz Bip., herba (EMA/HMPC/48715/2017, Revision 1, 8 July 2020), traditional use for migraine prophylaxis after serious conditions have been excluded by a doctor, adults and elderly: powdered herb 100 mg once daily or 200 mg three times daily (daily 100–600 mg). Not recommended under 18 years. [P10]
Pregnancy and breastfeeding
- NCCIH: do not take feverfew while pregnant because it may affect uterine contractions; little is known about safety while breastfeeding. [P5]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- NCCIH. Feverfew: Usefulness and Safety (Last Updated: February 2025), 2025-02. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Feverfew (last updated December 30, 2024), 2024-12-30. mskcc.org
- Heptinstall S, et al. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 1992;44(5):391-395 (PMID 1359053), 1992-05. pubmed.ncbi.nlm.nih.gov
- Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. Am J Health Syst Pharm 2002;59(16):1527-1531 (PMID 12185827), 2002-08-15. pubmed.ncbi.nlm.nih.gov
- Curry EA 3rd, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22(3):299-305 (PMID 15122077), 2004-08. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Tanacetum parthenium (L.) Schultz Bip., herba, EMA/HMPC/48715/2017 (Final, Revision 1, 8 July 2020), 2020-07-08. ema.europa.eu
Sources
- NCCIH. Feverfew: Usefulness and Safety (last updated February 2025), 2025-02. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Feverfew (last updated December 30, 2024), 2024-12-30. mskcc.org
- Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews 2015, Issue 4, CD002286, 2015-04-20. cochrane.org
- European Medicines Agency. Tanaceti parthenii herba: herbal medicinal product (monograph Rev. 1 published 14/08/2020), 2020-08-14. ema.europa.eu
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.